covid-19 vaccine infection

COVID-19 vaccine response weakened by common IBD drug

www.medicalnewstoday.com

inflammatory bowel disease (IBD) may have limited protection after their first COVID-19 vaccine dose, according to a new study.The research found that people using the biologic drug infliximab (Remicade), which belongs to the anti-tumor necrosis factor (anti-TNF) class of drugs, had significantly lower antibody concentrations after their first dose of a COVID-19 vaccine than people using an alternative biologic called vedolizumab (Entyvio).

This drug has a different mode of action and belongs to the gut-specific integrin receptor antagonist class of drugs.However, in a subgroup of people who had previously had SARS-CoV-2, and in a few people who had already had a second vaccine dose, the antibody response increased significantly.Stay.

Read more on medicalnewstoday.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News